Evolving molecular ther apy for chronic myeloid leukaemia - are we on target?

被引:37
作者
Copland, M
Jorgensen, HG
Holyoake, TL
机构
[1] Univ Glasgow, Royal Infirm, Div Canc Sci, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Sect Expt Haematol & Haemopoiet Stem Cells, Div Canc Sci & Mol Pathol, Glasgow G31 2ER, Lanark, Scotland
关键词
D O I
10.1080/10245330500234195
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myeloid leukaemia (CML) is a clonal disease of stem cell origin that develops when a single pluripotent haemopoietic stem cell acquires the Philadelphia (Ph) chromosome. The unique fusion gene product translated, p210 (Bcr-Abl), is a constitutively active tyrosine kinase that is specific to, and has a central role in the pathogenesis of, CML, making it an atractive target for drug therapy. Imatinib mesylate (IM) is one such therapy that also targets Abl, c-kit and PDGF-R tyrosine kinases. Although IM induces a much higher rate of complete cytogenetic remission (CCR), with improved tolerability and better progression free survival compared to other licensed therapies, resistance is a significant clinical problem. The most common mechanism of IM resistance is mutation of the Bcr-Abl kinase catalytic domain. In addition, molecular persistence in patients in CCR is most likely attributable to persisting Ph+ stem cells that are insensitive to IM by unknown mechanisms and this is a major focus of current research interest. Current results from pre-clinical in vitro work on novel agents and combination strategies as well as clinical trials including immunotherapy approaches are reviewed. Despite the widespread use of molecularly targeted therapies and the development of new therapeutic drugs and strategies, it is our belief that there is a requirement for further research into and development of stem cell-directed therapies to overcome molecular persistence. It is likely that a combination of molecularly targeted therapies or treatment modalities will finally eliminate the quiescent stem cell population, leading to a "molecular cure" of CML.
引用
收藏
页码:349 / 359
页数:11
相关论文
共 104 条
[1]   Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides [J].
Aichberger, KJ ;
Mayerhofer, M ;
Krauth, MT ;
Skvara, H ;
Florian, S ;
Sonneck, K ;
Akgul, C ;
Derdak, S ;
Pickl, WF ;
Wacheck, V ;
Selzer, E ;
Monia, BP ;
Moriggl, R ;
Valent, P ;
Sillaber, C .
BLOOD, 2005, 105 (08) :3303-3311
[2]  
Avery S, 2003, BLOOD, V102, p969A
[3]   Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia [J].
Baccarani, M ;
Martinelli, G ;
Rosti, G ;
Trabacchi, E ;
Testoni, N ;
Bassi, S ;
Amabile, M ;
Soverini, S ;
Castagnetti, F ;
Cilloni, D ;
Izzo, B ;
de Vivo, A ;
Messa, E ;
Bonifazi, F ;
Poerio, A ;
Luatti, S ;
Giugliano, E ;
Alberti, D ;
Fincato, G ;
Russo, D ;
Pane, F ;
Saglio, G .
BLOOD, 2004, 104 (13) :4245-4251
[4]  
Balabanov S, 2004, BLOOD, V104, p808A
[5]  
BEDI A, 1994, BLOOD, V83, P2038
[6]   Feasibility of imatinib combination therapies in a Randomized trial for chronic myeloid leukemia: The German CML-Study IV - pilot phase. [J].
Berger, U ;
Hochhaus, A ;
Reiter, A ;
Pfirrmann, M ;
Schoch, C ;
Ehninger, G ;
Fischer, T ;
Gratwohl, A ;
Hasford, J ;
Heimpel, H ;
Hossfeld, DK ;
Kolb, HJ ;
Krause, S ;
Ned, C ;
Pralle, H ;
Tobler, A ;
Hehlmann, R .
BLOOD, 2004, 104 (11) :11A-11A
[7]   Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].
Bhatia, R ;
Holtz, M ;
Niu, N ;
Gray, R ;
Snyder, DS ;
Sawyers, CL ;
Arber, DA ;
Slovak, ML ;
Forman, SJ .
BLOOD, 2003, 101 (12) :4701-4707
[8]   INTERFERON-ALPHA RESTORES NORMAL ADHESION OF CHRONIC MYELOGENOUS LEUKEMIA HEMATOPOIETIC PROGENITORS TO BONE-MARROW STROMA BY CORRECTING IMPAIRED BETA-1 INTEGRIN RECEPTOR FUNCTION [J].
BHATIA, R ;
WAYNER, EA ;
MCGLAVE, PB ;
VERFAILLIE, CM .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :384-391
[9]  
Bocchia M, 2003, BLOOD, V102, p30A
[10]   Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry [J].
Brümmendorf, TH ;
Holyoake, TL ;
Rufer, N ;
Barnett, MJ ;
Schulzer, M ;
Eaves, CJ ;
Eaves, AC ;
Lansdorp, PM .
BLOOD, 2000, 95 (06) :1883-1890